Down-regulation of BTG1 by miR-454-3p enhances cellular radiosensitivity in renal carcinoma cells
© Wu et al.; licensee BioMed Central Ltd. 2014
Received: 29 January 2014
Accepted: 8 August 2014
Published: 12 August 2014
B cell translocation gene 1 (BTG1) has long been recognized as a tumor suppressor gene. Recent reports demonstrated that BTG1 plays an important role in progression of cell cycle and is involved in cellular response to stressors. However, the microRNAs mediated regulatory mechanism of BTG1 expression has not been reported so far. MicroRNAs can effectively influence tumor radiosensitivity by preventing cell cycle progression, resulting in enhancement of the cytotoxicity of radiotherapy efficacy. This study aimed to demonstrating the effects of microRNAs on the BTG1 expression and cellular radiosensitivity.
The human renal carcinoma 786-O cells were treated with 5 Gy of X-rays. Expressions of BTG1 gene and miR-454-3p, which was predicted to target BTG1 by software algorithm, were analyzed by quantitative polymerase chain reaction. Protein expressions were assessed by Western blot. Luciferase assays were used to quantify the interaction between BTG1 3′-untranslated region (3′-UTR) and miR-454-3p. The radiosensitivity was quantified by the assay of cell viability, colony formation and caspase-3 activity.
The expression of the BTG1 gene in 786-O cells was significantly elevated after treatments with X-ray irradiation, DMSO, or serum starvation. The up-regulation of BTG1 after irradiation reduced cellular radiosensitivity as demonstrated by the enhanced cell viability and colony formation, as well as the repressed caspase-3 activity. In comparison, knock down of BTG1 by siRNA led to significantly enhanced cellular radiosensitivity. It was found that miR-454-3p can regulate the expression of BTG1 through a direct interaction with the 3′-UTR of BTG1 mRNA. Decreasing of its expression level correlates well with BTG1 up-regulation during X-ray irradiation. Particularly, we observed that over-expression of miR-454-3p by transfection inhibited the BTG1 expression and enhanced the radiosensitivity. In addition, cell cycle analysis showed that over-expression of miR-454-3p shifted the cell cycle arrest from G2/M phase to S phase.
Our results indicate that BTG1 is a direct target of miR-454-3p. Down-regulation of BTG1 by miR-454-3p renders tumor cells sensitive to radiation. These results may shed light on the potential application in tumor radiotherapy.
KeywordsmicroRNA BTG1 miR-454-3p Radiosensitivity S phase arrest
Enhancing the radiosensitivity of resistant tumor cells is a common emphasis in the application of clinical radiotherapy . Tumor suppressor genes that regulate cell cycle can alter the radiosensitivity of cancer cells. For example, down-regulation of RB1 correlates with increased apoptosis induced by radiation in human breast cancer cells [2, 3]; the mutations in the p53 tumor suppressor gene enhances the radiosensitivity in oral cavity carcinoma cells ; and P21 deficiency is associated with a radiosensitive phenotype in colorectal carcinoma cells . The RB1, p53 and p21 are tumor suppressor genes and play cruical roles in controlling the progression of cell cycle [6, 7]. These findings indicate that cell cycle regulation genes may be intimately related to radiosensitization, therefore, could potentially be exploited in tumor radiotherapy. In this study, the human renal carcinoma cell, which has traditionally been considered to be radioresistant , was used as experimental model.
B cell translocation gene 1 (BTG1) is another tumor suppressor gene [9, 10]. The BTG1 protein, together with five additional proteins (BTG2/PC3/Tis21, BTG3/ANA, BTG4/PC3B, Tob1/Tob, and Tob2), comprise the BTG/TOB family of anti-proliferative genes involved in the regulation of cell growth . Expression of BTG1 not only inhibits the proliferation of cells but also leads to G1 phase cell cycle arrest in multiple types of cells [12–14]. Some studies have shown that BTG1 is involved in the general processes of cell cycle control and in cellular responses to stress , though a specific role for BTG1 in renal cell carcinoma has not been determined. In consideration of the common physiological function of tumor suppressor genes in controlling cell cycle, we propose that BTG1 may have a similar impact as RB1, p53, and p21 on the radiosensitivity of renal carcinoma tumor cells.
Certain members of the BTG/TOB family are known to be regulated by microRNAs (miRNAs) , which are small non-coding RNA molecules that suppress gene expression via sequence-specific interactions with the 3′-untranslated region (3′-UTR) of their target transcripts . For example, BTG2 was shown to be suppressed by miR-21 ; over-expression of miR-142-5p leads to down-regulation of BTG3; and TOB2 was shown to be a target gene of miR-322 . However, miRNA candidates that target BTG1 have not been identified.
The strategy of using miRNAs as therapeutic targets to enhance cellular radiosensitivity has been discussed before . miRNAs can efficiently modulate tumor radiosensitivity at four aspects containing DNA damage repair, radio-related signal transduction pathways, tumor microenvironment and apoptosis [22, 23]. Recent reports show that miRNAs can effectively influence tumor radiosensitivity by impeding cell cycle progression, resulting in enhancement of radiotherapy efficacy . For example, miR-21 can improve tumor radiosensitivity and promote apoptosis through negatively regulating the CDC25A expression and cell cycle progression . Up-regulation of miR-504 can reduce p53 protein level and affect cell cycle arrest and radiosensitivity mediated by p53 . With these precedents, we tested whether the BTG1 could be regulated by miRNAs upon irradiation and how the cellular radiosensitivity in renal carcinoma cells could be affected by the changes of miRNAs targeting BTG1.
Cell culture and irradiation
Human renal carcinoma 786-O cells were cultured in RPMI-1640 media (GIBCO, NY, USA) supplemented with 10% fetal bovine serum (Hyclone, MA, USA) at 37°C and 5% CO2. Irradiation was carried out by laboratory X-ray source (RX-650, Faxitron Bioptics, USA) . The dose rate was 0.8 Gy/min (100 keV, 5 mA). Cells were seeded into 12-well plates and grown to <70% confluence at the time of irradiation.
Cell cycle assay
Cells were harvested and fixed as described previously . Prior to analysis, fixed cells were washed twice with PBS, treated with 100 μg/mL RNase A and 50 μg/mL propidium iodide (BD Biosciences, California, USA) for 20 min, and analyzed using FACS Calibur flow cytometry (Becton Dickinson, NJ, USA). Cell cycle distribution was analyzed with the FlowJo software package. DNA content of samples was measured with CellQuest (Becton Dickinson).
Western blot analysis
Western blotting was performed as described previously . Briefly, cells were collected and lysed with RIPA buffer solution (Beyotime, Haimen, China). Supernatants were collected at 10,000 g for 10 min at 4°C. The concentrations of samples were determined using a BCA protein assay kit (Pierce, IL, USA). Equal amounts of protein were loaded onto 10% SDS-polyacrylamide gels for electrophoresis, and proteins were transferred onto PVDF membrane by western blotting. GAPDH was used as loading control. Membranes were then blocked with nonfat milk and incubated overnight at 4°C with the following primary antibodies: anti-GAPDH (1:5,000, Santa Cruz), anti-BTG1 (1:1,000, Abnova, Taipei, Taiwan). Immunological complexes were detected by enhanced electrochemiluminescence (Millipore, Darmstadt, Germany) with either an anti-rabbit peroxidase (1:5000, Santa Cruz, Texas, USA), or an anti-mouse peroxidase (1:4000, Santa Cruz) antibody. The fold changes of protein levels were analyzed by the Image J software.
MicroRNA mimic and negative control mimic were synthesized and purified by RiboBio Co. (Guangzhou, China) . Transfections of the miRNA duplexes were performed with 40–60% confluent cells using Lipofectamine 2000 (Invitrogen, California, USA). The medium was replaced with new culture medium for 5 h after transfection.
Trypan blue dye exclusion assay
Cell viability is calculated as the number of viable cells divided by the total number of cells within the grids on the hemacytometer. Cells which take in trypan blue are considered non-viable. Cells were harvested with trypsin, suspended in PBS and mixed with 0.4% solution of trypan blue stain (Invitrogen) after various treatments. Count at least 500 cells for calculation. The percentage of viable cells = [1.00 - (Number of blue cells/Number of total cells)]*100%.
Caspase-3 activity assay
To evaluate the activity of caspase-3, the caspase-3 activity kit (Beyotime) was used. Cells were collected and lysed with reaction buffer and the total protein concentration is 1-3 mg/mL. In the samples, activated caspase-3 cleaves substrate (Ac-DEVD-pNA) (2 mM) between DEVD and pNA, quantitatively generating pNA that can be detected using an ELISA reader at an absorbance of 405 nm. In the caspase-3 colorimetric calibration, the value of R2 should be greater than 0.999.
Colony formation assay
The clonogenic assay was conducted as described previously . Briefly, cells were harvested and an appropriated number of cells were seeded onto each of the 60 mm dishes to produce about 50–120 colonies. After 8–10 days incubation, the colonies were washed with 1 × PBS softly, fixed with 70% ethanol for 5 min and stained with 0.5% crystal violet for 3 min at room temperature. Colonies with more than 50 cells were counted.
Luciferase reporter assay
The 3′-untranslated region (3′-UTR) of human BTG1 transcript was cloned downstream of the luciferase gene between the Xho I and Sal I sites of the pmirGLO dual-luciferase vector (Promega, WI, USA). A pmirGLO dual-luciferase vector containing one mutated seed sequences of miR-454-3p was constructed. The sequencing of constructed plasmids was verified by Shanghai Sangon Biotechnology Co. (Shanghai, China). 1.5 × 105 786-O cells in 12-well plate were co-transfected with 300 ng DNA (pmirGLO-3′ UTR constructs or derived mutants) and 30 nM of either miR-454-3p mimics using transfection reagent Lipofectamine 2000 (Invitrogen). Luciferase activity was measured 48 h later using the Dual Luciferase Reporter Assay System (Promega)  with a Tecan Infinite M200 Pro microplate reader (Tecan, Mannedorf, Switzerland).
Quantitative real-time reverse transcription-PCR
For qRT-PCR, total RNAs were extracted from cultured cells using TRIzol Reagent (Invitrogen) according to the manufacturer’s protocol. Reverse transcription and quantitative RT-PCR were performed according to the protocol of the qRT-PCR Detection Kit (Promega). All of the stem-loop RT primers were purchased from RiboBio Co. (Guangzhou, China) to detect miR-454-3p or U6. U6 was used as an endogenous control for miRNAs and GAPDH for coding genes. Other gene-specific primers were as follows: BTG1, 5′-TCCATAATCCATCCCCAAGA-3′ and 5′-GGATGCAATCCTGGACATTT-3′, SKA2, 5′-CCGCTTTAAACCAGTTGCTG-3′ and 5′-CTCTGCCGCAGTTTTCTCTT-3′, GAPDH, 5′-GTGGACCTGACCTGCCGTCT-3′ and 5′-GGAGGAGTGGGTGTCGCTGT-3′. Gene-specific primers were synthesized from Shanghai Sangon Biotechnology Co. (Shanghai, China).
All experiments were repeated at least three times, and data were presented as means ± SE. The statistical significance of the results was determined by Student’s t-tests using Microsoft Excel (Microsoft Campus, Redmond, WA, USA).
BTG1 is induced in response to ionizing radiation
Tumor cell sensitivity to IR correlates with BTG1 levels
To estimate radiosensitivity, the cell viability was assessed by trypan blue dye exclusion assay . In this study, transfection of 786-O cells with pcDNA3.0-BTG1 significantly increased cell viability after radiation exposure (Figure 2B). To further confirm the effects of BTG1 on radiosensitivity, we measured the activity of caspase-3 (see Methods) which is an acknowledged effector among the caspase family members involved in apoptosis . In order to more accurately characterize the changes of caspase-3 activity among all treatments, we drew standard curve and tested the caspase-3 activity at 24 h after irradiation (Additional file 1A and B). At 24 h after exposure to 5 Gy of X-rays, compared to transfection of pcDNA3.0, treatment of 786-O cells with transfection of pcDNA3.0-BTG1 caused a significant decrease in caspase-3 activation (Figure 2C). A colony formation assay was performed to determine the cellular radiation sensitivity. The survival fraction of 786-O cells transfected with pcDNA3.0-BTG1 without irradiation was significantly lower than that transfected with pcDNA3.0, due to the fact that BTG1 is an anti-proliferative gene. It is worth noting that there was no statistically significant difference in the survival fraction of cells exposed to 5 Gy of X-rays, when the group transfected pcDNA3.0-BTG1 was compared with the pcDNA3.0 group (Figure 2D and E). We also used flow cytometry to quantify changes in the sub-G1 peak at 48 h. The peak of transfection of BTG1 expression vector was decreased upon exposure to IR compared to the untransfected (Blank) group and the pcDNA3.0 group (Additional file 1C). These results suggest that BTG1 expression protects cells from the cytotoxic effects of IR.
BTG1 is a direct target of miR-454-3p
To analyze whether BTG1 can be regulated by miRNAs, we used starBase (sRNA target Base), a miRNA-mRNA interaction prediction software consisting of five different algorithms, to predict the miRNAs which may potentially target the 3′-UTR of the BTG1 mRNA . We selected the miRNAs that were predicted to target BTG1 by four or more algorithms for further analysis. These miRNAs included hsa-mir-130, hsa-mir-301a, hsa-mir-302, hsa-mir-454-3p, and hsa-mir-19b. Next, we constructed a series of pcDNA3.0 vectors that over-express these miRNAs and screened for those that regulate endogenous BTG1 levels at 48 h after transfection in 786-O cells. The BTG1 protein levels in samples transfected with pcDNA3.0-miR-454-3p displayed a significant down-regulation (Additional file 2F), indicating that miR-454-3p can target BTG1. A reproducible repression of endogenous BTG1 protein was also observed for vectors expressing miR-19b and miR-130, suggesting the possibility that multiple miRNAs target BTG1.
To determine whether endogenous miR-454-3p levels are regulated physiologically by IR, we assessed miR-454-3p expression in 786-O cells over a timecourse of exposure to 5 Gy of X-rays. While BTG1 mRNA levels increased, miR-454-3p levels decreased upon treatment (Figure 4E). It is worth noting that the BTG1 mRNA level decreased at 16 h after irradiation, whereas the miR-454-3p level increased.
The miR-454-3p gene is located in the first intron of the host gene, SKA2 (spindle and kinetochore-associated protein 2), which plays a critical role in proper mitotic progression, checkpoint silencing, and timely anaphase onset . To test whether the expression of SKA2 correlates with that of miR-454-3p, SKA2 mRNA was quantified by qRT-PCR. Similar to the results for miR-454-3p, the expression of SKA2 was down-regulated in 786-O cells after IR (Figure 4F), providing further verification of our findings. These results indicate that miR-454-3p regulates the expression of BTG1 through a direct interaction with the 3′-UTR of the BTG1, and that a decrease in its expression correlates with BTG1 up-regulation during IR treatment of renal carcinoma cells.
Suppression of BTG1 by miR-454-3p enhances cell sensitivity to IR and relieves the G2/M arrest induced by IR in 786-O cells
In the present study, we identified miR-454-3p as regulator of BTG1 expression based on bioinfomatic software prediction and detailed experimental validation. The expression of BTG1 and miR-454-3p was shown to inversely correlate in 786-O cells upon exposure to environmental stressors, thus supporting a physiological role for miR-454-3p in regulating BTG1 expression. In addition to miR-454-3p, miR-19b was predicted to have two binding sites on the 3′-UTR of the BTG1 mRNA, one of which occupies the same site as the putative miR-454-3p target. A significant repression of endogenous BTG1 protein by miR-19b expression vector was also observed in 786-O cells (Additional file 2F). Therefore, we speculate that more than one miRNA may target BTG1, and these miRNAs may function antagonistically under specific physiological conditions. Future experimentation to address this possibility may unveil a regulation network of BTG1 regulation by miRNAs.
Our results show that the expression of SKA2 is regulated coordinately with the expression of miR-454-3p. Interestingly, miR-454-3p and a third putative BTG1 target, miR-301a, are encoded within the first intron of SKA2, whose depletion affects the cell cycle by inducing a metaphase-like delay . MiR-301a also down-regulates the expression of an inhibitor of NF-κB, Nkrf . NF-κB binds directly to the SKA2 promoter region to activate the transcription of SKA2 and miR-301a and also enhances persistent NF-κB activation to facilitate tumor growth [37, 39], thus suggesting a feedback loop to moderate SKA2 function. It is intriguing that miR-454-3p targets BTG1, which has a strong anti-proliferative ability, and suggesting an additional complexity of the growth regulatory function derived from the SKA2 locus. BTG1 has been suggested to inhibit NF-κB activities . Therefore, complex regulatory loop appears to regulate cell growth inhibition by BTG1, and it is likely that SKA2, NF-κB and multiple miRNAs are coordinated to control the BTG1 expression.
Little is known about the molecular mechanisms of control of the cell cycle by BTG1, and most of the information comes from interaction studies. BTG1 exerts cellular functions by interacting with PRMT1, HOXB9, and hCAF1, which regulate the expression of a number of genes involved in cell cycle control and progression [41–43]. CCNA2 (cyclinA2) physically associates with BTG1  and controls S phase by activating CDK2 kinases to initiate DNA synthesis . Ectopic over-expression of CCNA2 triggers checkpoint response and subsequently increases the S phase population in mammalian cells . We found that siRNA-mediated silencing of BTG1 led to S phase arrest after IR. Additionally, the S phase arrest can also be mediated by miR-454-3p. Furthermore, miR-454-3p is highly expressed in the S phase. The above negative regulation may suggest the association between CCNA2 and BTG1 in the control of the cell cycle progression of S phase. However, our results also show that over-expression of BTG1 in 786-O cells promotes a G1 arrest. Therefore, the link between miR-454-3p, BTG1 and cell cycle is likely complex and warrants further investigation to unravel the network of cell cycle regulators that are functionally associated with BTG1.
In conclusion, our study reveals that BTG1 is a direct target of miR-454-3p. Changes of its expression levels render tumor cells sensitive to radiation due to the role of BTG1 in cell cycle progression. Therefore, down-regulation of BTG1 via miR-454-3p presents a possible strategy to sensitize tumor cells to radiotherapy.
This work was supported by the Major State Basic Research Development Program of China (973 Program, No. 2010CB834201), the National Natural Science Foundations of China (No. U1232125, 31270895, 11335011 and 31370846). We thank Qingxiang Gao and Liang Peng for their kind help of technology of flow cytometry; Torsten Juelich, Wenfei Li for critical reading of the manuscript.
- Terris DJ, Ho EY, Ibrahim HZ, Dorie MJ, Kovacs MS, Le QT, Koong AC, Pinto HA, Brown JM: Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay. Arch Otolaryngol Head Neck Surg 2002, 128: 698-702.View ArticlePubMedGoogle Scholar
- Carlson CA, Ethier SP: Lack of RB protein correlates with increased sensitivity to UV-radiation-induced apoptosis in human breast cancer cells. Radiat Res 2000, 154: 590-599.View ArticlePubMedGoogle Scholar
- Rosemann M, Gonzalez-Vasconcellos I, Domke T, Nathrath M, Atkinson MJ: Reduced Rb1 Expression Causes Impaired Genome Stability in Bone-Cells and Predispose for Radiation-Induced Osteosarcoma. In Radiobiology and Environmental Security, Chapter 29 Edited by: Mothersill CE, Korogodina V, Seymour CB. 2012, 353-364.View ArticleGoogle Scholar
- Pekkola-Heino K, Servomaa K, Kiuru A, Grenman R: Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma. Acta Otolaryngol 1996, 116: 341-344.View ArticlePubMedGoogle Scholar
- Huerta S, Gao XH, Dineen S, Kapur P, Saha D, Meyer J: Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts. Surgery 2013, 154: 143-151.View ArticlePubMedGoogle Scholar
- Hung S, Dalgard C, O’Brien J: Identification & characterization of novel small molecules with antiproliferative effects in Weri-Rb1 retinoblastoma cell line. J Invest Med 2009, 57: 207.Google Scholar
- Kobayashi T, Ishida J, Musashi M, Ota S, Yoshida T, Shimizu Y, Chuma M, Kawakami H, Asaka M, Tanaka J, Imamura M, Kobayashi M, Itoch H, Edamatsu H, Sutherland LC, Brachmann RK: p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. Int J Cancer 2011, 128: 304-318.View ArticlePubMedGoogle Scholar
- Stanic S, Boike T, Rule W, Timmerman R: Is renal cell carcinoma really radioresistant? Experience with stereotactic body radiation therapy in patients for primary and metastatic renal cell carcinoma. Am J Clin Oncol 2010, 33: 206.Google Scholar
- Holland ND, Zhang SC, Clark M, Panopoulou G: Sequence and developmental expression of AmphiTob, an amphioxus homolog of vertebrate Tob in the PC3/BTG1/Tob family of tumor suppressor genes. Dev Dyn 1997, 210: 11-18.View ArticlePubMedGoogle Scholar
- van der Meer L, Levers M, van Emst L, van Galen JC, van Kessel AG, Kuiper RP, Hoogerbrugge P, van Leeuwen FN: A key role for tumor suppressor BTG1 in the regulation of metabolic stress responses: implications for asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood 2010, 116: 452-453.Google Scholar
- Matsuda S, Rouault J, Magaud J, Berthet C: In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett 2001, 497: 67-72.View ArticlePubMedGoogle Scholar
- Hata K, Nishijima K, Mizuguchi J: Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement. Exp Cell Res 2007, 313: 2356-2366.View ArticlePubMedGoogle Scholar
- Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L, Garoccio M, Germain D, Samarut J, Magaud JP: BTG1, a member of a new family of antiproliferative genes. EMBO J 1992, 11: 1663-1670.PubMed CentralPubMedGoogle Scholar
- Suk K, Sipes DG, Erickson KL: Enhancement of B-cell translocation gene-1 expression by prostaglandin E-2 in macrophages and the relationship to proliferation. Immunology 1997, 91: 121-129.PubMed CentralView ArticlePubMedGoogle Scholar
- Takeuchi S, Hirata KI, Rikitake Y, Shimokawa Y, Kojima Y, Inoue N, Kawashima S, Yokoyama M: BTG1, an anti-proliferative gene, regulates endothelial cell growth and angiogenesis. Circulation 2001, 104: 34.View ArticleGoogle Scholar
- Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Janne OA, Seppala J, Lahdesmaki H, Tammela TL, Visakorpi T: Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 2012, 31: 4460-4471.View ArticlePubMedGoogle Scholar
- Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116: 281-297.View ArticlePubMedGoogle Scholar
- Liu M, Wu H, Liu T, Li Y, Wang F, Wan H, Li X, Tang H: Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res 2009, 19: 828-837.View ArticlePubMedGoogle Scholar
- Kee HJ, Park S, Kwon JS, Choe N, Ahn Y, Kook H, Jeong MH: B cell translocation gene, a direct target of miR-142-5p, inhibits vascular smooth muscle cell proliferation by down-regulating cell cycle progression. FEBS Lett 2013, 587: 2385-2392.View ArticlePubMedGoogle Scholar
- Gamez B, Rodriguez-Carballo E, Bartrons R, Rosa JL, Ventura F: MicroRNA-322 (miR-322) and its target protein Tob2 modulate Osterix (Osx) mRNA stability. J Biol Chem 2013, 288: 14264-14275.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao LQ, Bode AM, Cao Y, Dong ZG: Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis 2012, 33: 2220-2227.PubMed CentralView ArticlePubMedGoogle Scholar
- Kasinski AL, Slack FJ: MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011, 11: 849-864.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao LQ, Chen X, Cao Y: New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim Biophys Sin 2011, 43: 831-839.View ArticlePubMedGoogle Scholar
- Yang XJ, Feng M, Jiang X, Wu ZL, Li ZM, Aau MY, Yu Q: miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev 2009, 23: 2388-2393.PubMed CentralView ArticlePubMedGoogle Scholar
- de Oliveira PEQ, Zhang L, Wang ZH, Lazo JS: Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21. Cell Cycle 2009, 8: 3157-3164.View ArticlePubMedGoogle Scholar
- Hu WW, Chan CS, Wu R, Zhang C, Sun Y, Song JS, Tang LH, Levine AJ, Feng ZH: Negative regulation of tumor suppressor p53 by MicroRNA miR-504. Mol Cell 2010, 38: 689-699.PubMed CentralView ArticlePubMedGoogle Scholar
- Hu W, Pei H, Li H, Ding N, He J, Wang J, Furusawa Y, Hirayama R, Matsumoto Y, Liu C, Kawata T, Zhou G: Effects of shielding on the induction of 53BP1 foci and micronuclei after Fe ion exposures. J Radiat Res 2013, 55: 10-16.PubMed CentralView ArticlePubMedGoogle Scholar
- Ye C, Zhang X, Wan J, Chang L, Hu W, Bing Z, Zhang S, Li J, He J, Wang J, Zhou G: Radiation-induced cellular senescence results from a slippage of long-term G2 arrested cells into G1 phase. Cell Cycle 2013, 12: 1424-1432.PubMed CentralView ArticlePubMedGoogle Scholar
- Chang L, Hu WT, Ye CY, Yao B, Song L, Wu X, Ding N, Wang JF, Zhou GM: miR-3928 activates ATR pathway by targeting Dicer. RNA Biol 2012, 9: 1247-1254.PubMed CentralView ArticlePubMedGoogle Scholar
- Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 2006, 1: 2315-2319.View ArticlePubMedGoogle Scholar
- Connelly CM, Thomas M, Deiters A: High-throughput luciferase reporter assay for small-molecule inhibitors of microRNA function. J Biomol Screen 2012, 17: 822-828.PubMed CentralView ArticlePubMedGoogle Scholar
- Apicelli AJ, Robinson CG, Simpson JR, Gutmann DH: Reduced brain neurofibromatosis type 1 (Nf1) tumor suppressor gene expression confers differential sensitivity to ionizing radiation in vivo. Int J Radiat Oncol 2013, 87: S630.View ArticleGoogle Scholar
- Shi L, Chen JA, Yang JA, Pan TH, Zhang SG, Wang ZM: MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010, 1352: 255-264.View ArticlePubMedGoogle Scholar
- Liang CH, Chan LP, Chou TH, Chiang FY, Yen CM, Chen PJ, Ding HY, Lin RJ: Brazilein from Caesalpinia sappan L. Antioxidant Inhibits Adipocyte Differentiation and Induces Apoptosis through Caspase-3 Activity and Anthelmintic Activities against Hymenolepis nana and Anisakis simplex. Evid Based Complement Alternat Med 2013, 2013: 864892.PubMed CentralPubMedGoogle Scholar
- Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH: starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res 2011, 39: D202-D209.PubMed CentralView ArticlePubMedGoogle Scholar
- Hanisch A, Sillje HH, Nigg EA: Timely anaphase onset requires a novel spindle and kinetochore complex comprising Ska1 and Ska2. EMBO J 2006, 25: 5504-5515.PubMed CentralView ArticlePubMedGoogle Scholar
- Cao G, Huang B, Liu Z, Zhang J, Xu H, Xia W, Li J, Li S, Chen L, Ding H, Zhao Q, Fan M, Shen B, Shao N: Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting MEOX2 to affect ERK/CREB pathways. Biochem Biophys Res Commun 2010, 396: 978-982.View ArticlePubMedGoogle Scholar
- Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R, Li Y: miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J 2011, 30: 57-67.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen Z, Chen LY, Dai HY, Wang P, Gao S, Wang K: miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. J Cell Biochem 2012, 113: 3229-3235.View ArticlePubMedGoogle Scholar
- Cho IJ, Lee AK, Lee SJ, Lee MG, Kim SG: Repression by oxidative stress of NOS and cytokine gene induction in macrophages results from AP-1 and NF-kappa B inhibition mediated by B cell translocation gene-1 activation. Free Radic Biol Med 2005, 39: 1523-1536.View ArticlePubMedGoogle Scholar
- Lin WJ, Gary JD, Yang MC, Clarke S, Herschman HR: The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J Biol Chem 1996, 271: 15034-15044.View ArticlePubMedGoogle Scholar
- Prevot D, Voeltzel T, Birot AM, Morel AP, Rostan MC, Magaud JP, Corbo L: The leukemia-associated protein Btg1 and the p53-regulated protein Btg2 interact with the homeoprotein Hoxb9 and enhance its transcriptional activation. J Biol Chem 2000, 275: 147-153.View ArticlePubMedGoogle Scholar
- Prevot D, Morel AP, Voeltzel T, Rostan MC, Rimokh R, Magaud JP, Corbo L: Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: involvement in estrogen receptor alpha signaling pathway. J Biol Chem 2001, 276: 9640-9648.View ArticlePubMedGoogle Scholar
- Bogdan JA, Adams-Burton C, Pedicord DL, Sukovich DA, Benfield PA, Corjay MH, Stoltenborg JK, Dicker IB: Human carbon catabolite repressor protein (CCR4)-associative factor 1: cloning, expression and characterization of its interaction with the B-cell translocation protein BTG1. Biochem J 1998,336(Pt 2):471-481.PubMed CentralView ArticlePubMedGoogle Scholar
- Das E, Jana NR, Bhattacharyya NP: MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh (Q111)/Hdh (Q111) cells. Biochem Biophys Res Commun 2013, 437: 217-224.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.